Cytomegalovirus is one of the most important infections to occur after allogeneic
haematopoietic stem cell transplantation (HSCT), and an increasing number of reports …

Human cytomegalovirus (HCMV) reactivation is a major infectious cause of morbidity and
mortality after allogeneic hematopoietic stem cell transplantation (HSCT). HCMV is a …

Abstract The Practice Guidelines Committee of the American Society for Transplantation and
Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to …

Administration of posttransplant cyclophosphamide (PTCy) has significantly expanded the
number of patients undergoing HLA-haploidentical hematopoietic cell transplantation (haplo …

Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated
with poor outcomes, especially in high‐risk AML/MDS. Allogeneic hematopoietic stem cell …

A novel anti-cytomegalovirus (CMV) agent, letermovir (LMV), could reportedly improve the
outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) recipients because of …

The recent approval of letermovir marks a new era of therapy for human cytomegalovirus
(HCMV) infections, particularly for the prevention of HCMV disease in hematopoietic stem …

Severe infections and their attributable mortality are major complications in recipients of
allogeneic hematopoietic stem cell transplantation (alloSCT). We herein report 236 adult …

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment
for some inherited disorders, including selected primary immunodeficiencies (PIDs). In the …

Promising results have been reported for patients with high-risk hematologic malignancies
undergoing HLA-haploidentical bone marrow transplantation (haploBMT) with …